Every peptide here engages the body's own growth-hormone axis—the brain-to-pituitary chain that decides how much growth hormone is released—but each is studied with a different research emphasis. They are not interchangeable and are not expected to produce the same outcome. See how they fit together, find the one that matches the outcome you are studying, then compare them side by side.
HOW THEY FIT TOGETHER
Two switches, one output
The pituitary releases growth hormone when one of two receptors on it—think of them as switches—is turned on. Each single peptide here works one switch. The combinations work both at once.
Why combinations pair across switches. Two peptides on the same switch overlap: Tesamorelin and CJC-1295 both work the GHRH receptor, so pairing them mostly piles more stimulus onto one route. Adding Ipamorelin brings in the second route instead. Trials on the Ipamorelin/CJC-1295 blend itself are limited, and no published trial has evaluated the Ipamorelin + Tesamorelin pairing—each compound stands on its own record.
PICK BY RESEARCH GOAL
Which one fits your research?
Each option has its own job. Find the outcome you are studying, then read its details below.
If you are studying…
Start with
Training recovery and muscle-growth support, with the strongest GH pulse
Highlight one option to see its relative research emphasis across three growth-hormone outcomes. Ratings show relative research emphasis and typical research-use profile—not absolute GH output, not guaranteed results, and not head-to-head trial rankings. A combination's bar blends the colors of its two peptides.
Single peptides
Combinations
GH Release & Potency Relative GH-axis stimulation, by research emphasis
Ipamorelin/CJC
Strongest
Ipa + Tesa
Strong (two receptors)
Tesamorelin
Strong
CJC-1295
Pulse amplifier
Ipamorelin
Selective pulse
Sermorelin
Moderate
Muscle Growth & Recovery Training-recovery and lean-mass emphasis
Ipamorelin/CJC
Muscle-growth support
Ipa + Tesa
Muscle support, VAT-led
Tesamorelin
Lean-mass signal
CJC-1295
Recovery support
Ipamorelin
Recovery support
Sermorelin
Supportive
Visceral Fat Reduction Deep abdominal (VAT) fat emphasis
Tesamorelin
Targeted
Ipa + Tesa
Targeted (Tesamorelin-led)
Ipamorelin/CJC
Moderate
CJC-1295
Mild
Ipamorelin
Mild
Sermorelin
Mild
Dose context. Tesamorelin is typically studied at about 2 mg once daily. Ipamorelin/CJC-1295 is typically 200–300 mcg of each, one to two times daily, and Ipamorelin or CJC-1295 on its own about 300 mcg, usually at night. Sermorelin is typically about 400 mcg, usually at night. The bars are not equimolar or dose-matched, and none of this is a dosing recommendation.
GH release. Ipamorelin/CJC is rated strongest as a synergistic, multi-pulse stack acting on two receptors. Tesamorelin is a full-length GHRH analog that, at 2 mg daily, produced documented IGF-1 rises in Phase 3 trials. CJC-1295 and Ipamorelin each drive a pulse through one switch: CJC-1295 by amplifying the body's own GHRH signal, Ipamorelin through the ghrelin receptor with unusual selectivity. Sermorelin is the gentlest in this comparison.
Muscle. None of these is a primary muscle-building intervention; they are studied as support for recovery, lean-mass maintenance, and training adaptation. Ipamorelin/CJC is the usual choice for muscle-growth-support and training-recovery research (community use plus mechanism; blend-specific trials are limited). Tesamorelin has the only controlled human lean-mass data: roughly +1.2 to +1.4 kg lean body mass over 26 weeks versus placebo, plus increased trunk-muscle area and density in a secondary analysis. Ipamorelin and CJC-1295 on their own carry research-use recovery reports but no controlled body-composition trials. Sermorelin is gentle and supportive.
Visceral fat. Tesamorelin's evidence basis is a 15–20% visceral-fat reduction over about 26 weeks in Phase 3 HIV-lipodystrophy trials.
The pairing. The Ipamorelin + Tesamorelin bars combine each compound's own evidence—they are not results from a combined trial, because none has been published. BLP does not sell this pairing as a blend; it is two separate research vials.
The original growth-hormone-releasing peptide. It nudges the body to make its own growth hormone on its normal schedule rather than forcing a large spike, which is why it is studied for steady, long-term support—overall wellness, vitality, and hormonal balance.
Established: mechanism · Gentlest outcome profile in this comparison
The GHRH half of Ipamorelin/CJC-1295, on its own. It is the same active fragment as Sermorelin with four changes that protect it from rapid breakdown, so it lasts about 30 minutes and amplifies the body's own growth-hormone pulses while keeping their natural rhythm. The no-DAC form is short-acting on purpose: the long-acting DAC form flattens that rhythm.
Established: GHRH-receptor mechanism · Preliminary: recovery and body-composition outcomes (human data come mainly from the long-acting DAC form)
Specifically studied for deep abdominal (visceral) fat reduction—15–20% VAT reduction over about 26 weeks in Phase 3 trials—with a documented lean-mass and muscle-quality signal alongside, and IGF-1 rises that stay within or near the physiological range.
Established: visceral fat (VAT) · Modest / secondary: lean mass and muscle quality
Those focused on visceral fat loss
Waist circumference and metabolic-health goals
Lean-mass and trunk-muscle-quality signal alongside fat reduction
HIV-related fat redistribution (lipodystrophy) and abdominal-obesity research
The ghrelin-receptor half of Ipamorelin/CJC-1295, on its own. It is the most selective compound in its class: in the original pharmacology it released growth hormone without raising cortisol, prolactin, or other pituitary hormones, even at doses far above the effective one. It reached Phase 2 human trials; no controlled trial has studied it alone for body composition, recovery, or sleep.
Established: selectivity and GH release · Preliminary: recovery, sleep, and body-composition outcomes
A clean GH pulse without cortisol or prolactin rises
A 1:1 blend of Ipamorelin and CJC-1295 in one vial, delivering the strongest synergistic pulsatile GH release in this comparison (GHRH + ghrelin receptor). Studied for training recovery, muscle-growth support, and performance; human trials on the blend itself are limited.
Established: dual-pathway pharmacology · Preliminary: muscle-growth-support and body-composition outcomes
Training-recovery and muscle-growth-support research
Those wanting the strongest synergistic GH pulse
Body-composition research with a performance focus
A research pairing, not a blended product: Tesamorelin brings the only Phase 3 visceral-fat evidence in this comparison, and Ipamorelin adds a selective GH pulse through the other receptor (GHS-R1a). Where Ipamorelin/CJC leans muscle-growth support and recovery, this pairing is studied VAT-first with muscle support alongside. Each compound is scored on its own record—no published trial has evaluated the two together.
Established: each compound’s own mechanism and evidence · Unstudied: the specific combination
Visceral-fat (VAT) research that also wants muscle-growth support
Two-receptor GH-axis designs (GHRH-R + GHS-R1a)
Protocols anchored on Tesamorelin’s Phase 3 VAT evidence
Researchers weighing this against the Ipamorelin/CJC recovery focus
Ratings reflect each option's studied research emphasis relative to the others—not absolute GH output, effect sizes, head-to-head trial rankings, or a promise of results. All of them are offered strictly for laboratory and research use. See each compound page for its full Evidence Snapshot and research findings.
